Wednesday 18 June 2014

Selexipag Meets Primary Endpoint in Pivitol Phase III Griphon Outcome Study in Patients with Pulmonary Arterial Hypertension « New Drug Approvals

Selexipag Meets Primary Endpoint in Pivitol Phase III Griphon Outcome Study in Patients with Pulmonary Arterial Hypertension « New Drug Approvals:



'via Blog this'

No comments:

Post a Comment